Evapotranspiración y balance energético de un cultivo de soja en la región semiárida de Buenos Aires (Argentina)

Cargnel, M. D. Universidad de Buenos Aires. Facultad de Agronomía. Buenos Aires, Argentina.Orchansky, A. L. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires, Argentina.Brevedan, R. E. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires, Argentina.Baioni, S. S. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires´, Argentina.Fioretti, M. N. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires, Argentina.181-189Two field experiments were carried out in a semiarid region of Argentina over a soybean (Glycine max L. Merrill) field. The sites of study were San Adolfo (39˚ 23’ S, 62˚ 22’ W, 22 m.a.s.l.) and Nueva Roma (38˚ 29’ S, 62˚ 39’ W, 70 m.a.s.l.). Soybeans were planted on Jan 4 (San Adolfo) and Nov 27 (Nueva Roma) in 0.75 m wide rows and at 400000 pl/ha during two consecutive growing seasons. Energy balance and evapotranspiration (ET) were estimated during the reproductive stages from full bloom (R2) to full maturity (R8). In Nueva Roma ET or latent heat flux (LE) was estimated using the Bowen ratio-energy balance (BREB) (LEb) and the Priestley -Taylor equation (LEPT) with αPT=1.26, 48 h after irrigation or rain. Both methods could be used to predict ET since the ratio LEb/LEPT ranged between 0.83 and 0.95. The observed Bowen ratio values were almost 0 during and after rain and increased to approximately 0.45 several days after rain. In San Adolfo LE was estimating using the Priestley -Taylor equation. For both sites the regression analysis for comparison available energy (Rn-G) and LE using BREB or LEPT indicated that, approximately 90% of the available energy was consumed by LE without detecting significative advective conditions

Evapotranspiración y balance energético de un cultivo de soja en la región semiárida de Buenos Aires (Argentina)

Cargnel, M. D. Universidad de Buenos Aires. Facultad de Agronomía. Buenos Aires, Argentina.Orchansky, A. L. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires, Argentina.Brevedan, R. E. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires, Argentina.Baioni, S. S. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires´, Argentina.Fioretti, M. N. Universidad Nacional del Sur. Departamento de Agronomía. Bahía Blanca, Buenos Aires, Argentina.181-189Two field experiments were carried out in a semiarid region of Argentina over a soybean (Glycine max L. Merrill) field. The sites of study were San Adolfo (39˚ 23’ S, 62˚ 22’ W, 22 m.a.s.l.) and Nueva Roma (38˚ 29’ S, 62˚ 39’ W, 70 m.a.s.l.). Soybeans were planted on Jan 4 (San Adolfo) and Nov 27 (Nueva Roma) in 0.75 m wide rows and at 400000 pl/ha during two consecutive growing seasons. Energy balance and evapotranspiration (ET) were estimated during the reproductive stages from full bloom (R2) to full maturity (R8). In Nueva Roma ET or latent heat flux (LE) was estimated using the Bowen ratio-energy balance (BREB) (LEb) and the Priestley -Taylor equation (LEPT) with αPT=1.26, 48 h after irrigation or rain. Both methods could be used to predict ET since the ratio LEb/LEPT ranged between 0.83 and 0.95. The observed Bowen ratio values were almost 0 during and after rain and increased to approximately 0.45 several days after rain. In San Adolfo LE was estimating using the Priestley -Taylor equation. For both sites the regression analysis for comparison available energy (Rn-G) and LE using BREB or LEPT indicated that, approximately 90% of the available energy was consumed by LE without detecting significative advective conditions

Triple antiviral therapy in HCV positive patients who failed prior combination therapy

AIM: To assess the efficacy of triple therapy (peginte-rferon or high dose standard interferon, plus ribavirin and amantadine) in nonresponders to prior combination therapy. METHODS: A total of 196 patients were enrolled in a multicenter, open, randomized study. Patients were given 180 mug/wk of peginterferon-alpha-2a (40 kDa) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group A) or interferon-alpha-2a (6 MU/d for 4 wk, 3 MU/d for 20 wk, and 3 MU tiw for 24 wk) plus ribavirin (800-1000 mg/d) and amantadine (200 mg/d) for 48 wk (group B). RESULTS: Overall sustained virologic response (SVR) was 26.6% (32.1% and 19.5% in group A and B, P = 0.057). Baseline ALT > 120 UI/L (OR 2.4; 95% CI: 1.11 to 5.20; P = 0.026) and HCV RNA negativity after 12 wk (OR 8.7; 95% CI: 3.87 to 19.74; P < 0.0001) were independently associated with SVR. Therapy discontinuation occurred less frequently in patients treated with peginterferon than standard interferon (P = 0.036). CONCLUSION: More than 25% of nonresponders to combination therapy can eradicate HCV infection when retreated with triple therapy, especially if they have a high baseline ALT and are treated with pegylated interferon

Self-reported oral hygiene habits and periodontal symptoms among postpartum women

Purpose. The purpose of this study is to describe oral hygiene practices and periodontal symptoms among postpartum women and to assess whether self-reported periodontal symptoms are correlated with a clinical diagnosis of periodontal disease. Methods A self-administered questionnaire was developed to assess socio-demographic information, oral hygiene habits and frequency of dental visits among a group of 409 postpartum women. Additional questions included information on self-reported periodontal symptoms. Pregnancy information was obtained from medical charts. Results 99.3% of the participants brushed their teeth every day; 46.2 and 53.8% reported teeth brushing once a day or more, respectively. Periodontal disease was present in 61.4% of women. Patients with gum swelling and tooth mobility were almost twice as likely to have a periodontal disease (OR 1.7, CI 95% 0.9\u20132.8 and OR 1.7, CI 95%: 0.8\u20133.5, respectively). No associations were found between periodontal disease, gum swelling PTB and/or LBW. Conclusions Maternal clinical periodontal disease at delivery was related with self-perceived gum swelling and tooth mobility. Dentists and prenatal medical care providers may have the opportunity to target pregnant women that might be at higher risk for periodontal disease by asking whether they have tooth mobility and/or swollen gum

Analysis of allergenic residues in wines by triple quadrupole LCMS

During the winemaking are used technology coadjuvants, between them: albumin, caseinates and lysozyme. These compounds have great oenological properties, however, the presence of their residues can represent risks to people who are allergic to them because they are derived from eggs and milk. Mass spectrometry methods enables unambiguous determination of allergenic proteins at low levels in wines. Therefore, the aim of this study was to determine the concentrations of ovalbumin, alpha-casein, beta-casein and lysozyme in experimental wines treated with different concentrations of them by triple quadrupole liquid chromatography mass spectrometry with Jet Stream Electrospray Ionization (ESI). The wines were elaborated and treated with different concentrations of albumin, lysozyme and potassium caseinate. Bentonite and decantation were used for the removal of the fining agents. The quantification limits (LOQ) for ovalbumin, a-casein, b-casein and lysozyme were: 0.002 mg/L, 0.24 mg/L, 0.75 mg/L and 0.04 mg/L, respectively. Non residues of the proteins were identified in the experimental wines treated with the different amounts of potassium caseinate, albumin and lysozyme, analyzed in this study. These results provide an evidence of the absence of residues of caseinate, albumin and lysozyme in the concentrations tested in the wines if good treatment practices are followed

Bacteriological evaluation of vaccination against Salmonella Typhimurium with an attenuated vaccine in subclinically infected pig herds

Subclinical infections with Salmonella Typhimurium occur frequently in pigs. They constitute a risk for human salmonellosis and are difficult to control with currently available control measures. Vaccination against Salmonella Typhimurium in pigs can be an effective tool to control Salmonella infections at farm level. In the present study, the efficacy of an attenuated Salmonella Typhimurium vaccine (Salmoporc®, IDT Biologika) to control Salmonella infections in pigs was evaluated in three subclinically infected pig herds. The effect on Salmonella excretion and the number of pigs positive for Salmonella Typhimurium field and vaccine strains in ileocecal lymph nodes at slaughter were evaluated using five different vaccination strategies: 1. vaccination of sows, 2. vaccination of sows and piglets, 3. vaccination of sows and fattening pigs, 4. vaccination of piglets, 5. vaccination of fattening pigs, which were all compared to a non-vaccinated control group (experimental group 6). Each vaccination strategy was implemented in each farm, during two consecutive production cycles of the same sows. The prevalence of Salmonella Typhimurium field strain excretion was low; in total, 4% of the fecal and overshoe samples collected in the non-vaccinated control group were Salmonella Typhimurium field strain positive. The excretion of Salmonella Typhimurium field strain did not significantly differ between farms, production cycles and experimental groups. Applying vaccination in either sows and piglets, sows and fattening pigs, or in piglets only, resulted in a significantly reduced number of Salmonella Typhimurium field strain positive lymph nodes of slaughter pigs in the second production cycle, but not in the first production cycle. Vaccination of sows and piglets resulted in the most consistent reduction of Salmonella Typhimurium field strain positive lymph nodes at slaughter. The vaccine strain was detected in the lymph nodes of 13 pigs at slaughter, indicating the possible persistence of the vaccine strain until slaughter. Because of limitations in the study design, and the variability between farms and production cycles, the results of the current observational study should be extrapolated with care. Nevertheless, the results provide evidence that applying vaccination against Salmonella Typhimurium in sows and piglets (preferred), sows and fattening pigs, and piglets only can support the control of Salmonella Typhimurium infections by decreasing the prevalence of Salmonella Typhimurium field strain positive lymph nodes at slaughter

Aplastic Anemia Complicating Orthotopic Liver Transplantation for Non-A, Non-B Hepatitis

Aplastic anemia developed in 9 of 32 patients (28 percent) undergoing orthotopic liver transplantation for acute non-A, non-B hepatitis, at one to seven weeks after the procedure. No patient previously had evidence of hematologic dysfunction or conditions known to be associated with aplastic anemia. No other cases of aplastic anemia were identified among 1463 patients undergoing liver transplantation for all other indications at the four centers participating in the study (chi-square = 415, P<0.001; 95 percent confidence interval for the incidence of aplastic anemia after transplantation for non-A, non-B hepatitis, 13 to 44 percent, vs. 0.00 to 0.13 percent for all other indications). The operative and postoperative treatment of these patients was not otherwise different, indicating that the aplastic anemia was a complication of the hepatitis, not of the transplantation procedure. Four of the nine patients died of complications due to infections. Three of the surviving patients have been followed for less than six months, one for one year, and one for two years. The two patients followed the longest have recovered marrow function to an appreciable degree, and two of the others have evidence of early recovery. We conclude that patients undergoing orthotopic liver transplantation for non-A, non-B hepatitis are at a high risk for the development of aplastic anemia. (N Engl J Med 1988; 319:393–6.) © 1988, Massachusetts Medical Society. All rights reserved

Influence of IL28B Polymorphisms on Response to a Lower-Than-Standard Dose peg-IFN-α 2a for Genotype 3 Chronic Hepatitis C in HIV-Coinfected Patients

Background: Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients. Methods and Findings: Pilot, open-label, single arm clinical trial which involved 58 Caucasian HCV/HIV-coinfected patients who received weekly 135 μg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks after attaining undetectable viremia. The relationships between baseline patient-related variables, including IL28B genotype, plasma HCV-RNA, ribavirin dose/kg, peginterferon-α 2a and ribavirin levels with virological responses were analyzed. Only 4 patients showed lack of response and 5 patients dropped out due to adverse events related to the study medication. Overall, sustained virologic response (SVR) rates were 58.3% by intention-to-treat and 71.4% by per protocol analysis, respectively. Among patients with rapid virologic response (RVR), SVR and relapses rates were 92.6% and 7.4%, respectively. No relationships were observed between viral responses and ribavirin dose/kg, peginterferon-α 2a concentrations, ribavirin levels or rs129679860 genotype. Conclusions: Weekly 135 μg pegIFN-α 2a could be as effective as the standard 180 μg dose, with a very low incidence of severe adverse events. A 24-week treatment duration appears to be appropriate in patients achieving RVR, but extending treatment up to just 20 weeks beyond negativization of viremia is associated with a high relapse rate in those patients not achieving RVR. There was no influence of IL28B genotype on the virological responses. © 2012 López-Cortés et al.Funding provided by Fundación Pública Andaluza para la gestión de la Investigación en Salud de Sevilla. Hospitales Universitarios Virgen del Rocío. Seville, Spain. The enzyme-linked immunosorbent assay Hu-INF-α kits for determination of pegIFN-α-2a were financed by Roche Pharma, S.A. (Spain).Peer Reviewe

Gammaglutamyltranspeptidase (gamma-GT) levels before treatment are predictive of Tipranavir interruption in ART multiexperienced HIV-1-infected patients

The Italian Tipranavir EUP/EAP study was an observational study involving nine Italian centres that enrolled three class drug-experienced patients who consecutively entered the EUP/EAP TPV programs. The Cox model performed to assess the risk correlates of interrupting TPV included sex, age, HIV risk factors, HBV/HCV status, use of T20, CD4, HIV-RNA, ALT, γ-GT, cholesterol, triglycerides, glucose levels determination before starting TPV. The study enrolled 175 patients followed up for a median time of 30 weeks (range 3-68). TPV was interrupted by 46 patients (16 for intolerance, 14 for immuno-virological failure, four for disease progression – including two deceased – 12 for patient decision). The factors independently associated with treatment interruption for any cause were previous ART duration (OR 1.18, 95%CI 1.03-1.35, p=0.016 per each additional year) and γ-GT BL (grade 2 vs 0: OR 6.31, 95%CI 2.49-16.4, p< 0.0001). The γ-GT BL median level in the 16 patients who interrupted TPV for intolerance was 122 IU/L (range: 11-352). Both γ-GT and ALT were significantly increased at interruption compared to BL (p=0.041 and p=0.016 respectively, Wilcoxon test). A transient protective effect against γ-GT and TG increase was observed in patients receiving T20 with TPV (p=0.034 and p=0.027 respectively at week 12 in a Cox model assessing the risk of increasing one toxicity grade). γ-GT level seems to be relevant and more sensitive than ALT/AST level or HBV/HCV status in predicting the risk of TPV interruption. Unreported alcohol abuse could be considered a potential cofactor limiting the effectiveness and safety of TPV/RTV treatment